Search

1 to 10 of 202
Sort by

Library Entry
Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article evaluating, in three mouse models, the antitumoral effects induced by hypofractionated RT (hRT) plus IL-2c. We also used non-invasive imaging with a newly developed PET tracer based on therapeutically active IL-2c...



Library Entry
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small c

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article describing a phase Ib clinical trial evaluating treatment with BI1361849 combined with local radiation in 26 stage IV NSCLC patients with partial response (PR)/stable disease (SD) after standard first-line therapy...


Library Entry
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article in which researchers developed a hematopoietic humanized mouse model, hu-CB-BRGS, and used it to study anti-tumor human immune responses to triple-negative breast cancer (TNBC) cell line and patient-derived...


Library Entry
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article providing key clinical data in patients with solid epithelial tumors following treatment with IV enadenotucirev monotherapy and supports further investigation of enadenotucirev in combination with other...


Library Entry
Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article demonstrating that HMGN1/αCD4 treatment expanded effector CD8 + T cells and prolonged their anti-tumor activities by rescuing them from exhaustion, thus resulting in tumor regression and even rejection in long...


Library Entry
A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article showing that a novel PNU-armed, HER2-targeting ADC elicited long-lasting immune protection in a murine orthotopic breast cancer model resistant to other HER2-directed therapies. The findings delineate the...


Library Entry
Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article in which data shows that modulation of the tumor immune microenvironment with CTX/L-NIL enhances susceptibility of treatment-refractory tumors to CRT. Authors: Aurelie Hanoteau, Jared M. Newton , Rosemarie...


Library Entry
Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article where researchers explained how vaccination were combined with single low-dose chemotherapy as precondition to polarize immunosuppressive cells and thus modulate the immune system. Authors: Claudia Maletzki , ...


Library Entry
Advances in Cancer Immunotherapy™ Webinar Series: Updates from the Field - Clinical Updates from SITC 2018

This webinar provided an update on developments in the field relating to content presented at the Advances in Cancer Immunotherapy programs and focused on applicable information for a clinical audience. More specifically, program organizers Christian M. Capitini, MD, and Zachary S. Morris,...